Alnylam Pharma (ALNY) Misses Q2 EPS by 42c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $242.20 -1.35%
EPS Growth %: -39.0%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -39.0%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($2.03), $0.42 worse than the analyst estimate of ($1.61). Revenue for the quarter came in at $224.82 million versus the consensus estimate of $255.87 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
- Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
